What after MDS?

What after MDS?

Bibliographic Details
Main Author:	Vijay Deshmukh
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-01-01
Series:	Journal of International Clinical Dental Research Organization
Online Access:	http://www.jicdro.org/article.asp?issn=2231-0754;year=2014;volume=6;issue=1;spage=6;epage=6;aulast=Deshmukh

Similar Items

Why not MDS in dental material sciences?
by: Vijay Deshmukh
Published: (2016-01-01)

High-risk MDS after HMAs
by: Lionel Adès
Published: (2019-06-01)

Generalized GM-MDS: Polynomial Codes Are Higher Order MDS
by: Brakensiek, Joshua, et al.
Published: (2024)

MDS Constacyclic Codes and MDS Symbol-Pair Constacyclic Codes
by: Hai Q. Dinh, et al.
Published: (2021-01-01)

The weights in MDS codes
by: Ezerman, Martianus Frederic, et al.
Published: (2019)

Construction of MDS matrices
by: Peng-fei LI, et al.
Published: (2016-06-01)

More Constructions of Light MDS Transforms Based on Known MDS Circulant Matrices
by: Jin-Bo Wang, et al.
Published: (2022-07-01)

Application of classical Hermitian self-orthogonal MDS codes to quantum MDS codes
by: Jin, Lingfei, et al.
Published: (2012)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
by: Rafal Machowicz, et al.
Published: (2023-08-01)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

Inherited predisposition to MDS/AML
by: Ana Rio Machin, et al.
Published: (2018-06-01)

The impact of spliceosome mutations in MDS
by: Jacqueline Boultwood, et al.
Published: (2019-06-01)

MDS 2023: State of The Art
by: Moshe Mittelman
Published: (2023-10-01)

New quantum MDS codes
by: Zhang, Guanghui, et al.
Published: (2015)

MDS Matrices with Lightweight Circuits
by: Sébastien Duval, et al.
Published: (2018-06-01)

RECURRENCE OF UNDERLYING CONGENITAL NEUTROPENIA WITHOUT MDS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN A PATIENT WITH ELANE-MUTATED CONGENITAL NEUTROPENIA AND SECONDARY MDS
by: Ingrid Furlan, et al.
Published: (2023-12-01)

Diffusion analysis of EFN-MDS structure
by: Ibrahim, Subariah, et al.
Published: (2006)

Diffusion analysis of EFN-MDS structure
by: Ibrahim, Subariah
Published: (2006)

The role of innate immunity in MDS pathogenesis
by: David A. Sallman, et al.
Published: (2019-06-01)

Allogeneic Stem Cell Transplantation for MDS
by: Sara Villar, et al.
Published: (2021-08-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

On the Lower Bound of Cost of MDS Matrices
by: Ayineedi Venkateswarlu, et al.
Published: (2022-12-01)

The Coming of Age of Preclinical Models of MDS
by: Wei Liu, et al.
Published: (2022-03-01)

Targeting the Microenvironment in MDS: The Final Frontier
by: Patric Teodorescu, et al.
Published: (2020-07-01)

On Efficient Constructions of Lightweight MDS Matrices
by: Lijing Zhou, et al.
Published: (2018-03-01)

MDS plus data acquisition system
by: Stillerman, J.A., et al.
Published: (2015)

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
by: F. Schulz, et al.
Published: (2022-06-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Efficace, F, et al.
Published: (2024)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Controversies on the Consequences of Iron Overload and Chelation in MDS
by: Francesca Vinchi, et al.
Published: (2020-06-01)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

VEXAS Syndrome: A Novelty in MDS Landscape
by: Marie Templé, et al.
Published: (2022-06-01)

Aetiology of MDS: With a Focus on Hereditary Predisposition
by: Anjum B. Khan, et al.
Published: (2021-12-01)

TRISOMY 8 IN HIGH RISK MDS PATIENT
by: AC Chaves, et al.
Published: (2023-10-01)

Editorial: Advancing Science for Clinical Care in MDS
by: Maria E. Figueroa, et al.
Published: (2022-04-01)

On linear codes whose hermitian hulls are MDS
by: Luo, Gaojun, et al.
Published: (2024)

A construction of MDS quantum convolutional codes
by: Zhang, Guanghui, et al.
Published: (2015)

MDS coded caching with MRT and its optimization
by: Gibum Kim, et al.
Published: (2019-03-01)